Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients.
atopic dermatitis
cyclosporin
drug survival
dupilumab
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
02
06
2020
accepted:
03
07
2020
pubmed:
8
7
2020
medline:
29
4
2021
entrez:
8
7
2020
Statut:
ppublish
Résumé
Dupilumab and cyclosporin are recommended treatments for moderate-to-severe atopic dermatitis (AD). The objective of this study was to investigate drug survival of dupilumab in comparison with CsA, reasons of drug discontinuation, and predictive parameters of drug survival in daily practice. Retrospective study including patients with moderate-to-severe AD treated with dupilumab or cyclosporin (CsA) from January 1, 2019 to April 30, 2020. Drug survival analysis was performed using the Kaplan-Meier method and predictive factors were analyzed using multivariate Cox regression analyses. Adult patients with AD (n = 251) treated with dupilumab (n = 149) or CsA (n = 102) were included. Sixteen months from baseline, 82% of patients receiving dupilumab were still on treatment vs 11% of those treated with CsA. Reason for withdrawing dupilumab were primary inefficacy in 4.7% of patients, persistent clinical remission in 7.4%, and cutaneous adverse effects in 2.0%. Older age at diagnosis and shorter AD duration predicted shorter dupilumab survival. Reasons for CsA withdrawal included adverse effects in 23.5% of patients, persistent clinical remission in 15.6%, and a minimal or absent improvement in 11.7%. Dupilumab has a longer drug survival compared to CsA. Only a limited number of dupilumab patients discontinued treatment due to adverse effects and/or ineffectiveness.
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Pharmaceutical Preparations
0
dupilumab
420K487FSG
Cyclosporine
83HN0GTJ6D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13979Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73:1284-1293.
Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl. 1):8-16.
Kido-Nakahara M, Furue M, Ulzii D, Nakahara T. Itch in atopic dermatitis. Immunol Allergy Clin North Am. 2017;37:113-122.
Xerfan EMS, Tomimori J, Andersen ML, Tufik S, Facina AS. Sleep disturbance and atopic dermatitis: a bidirectional relationship? Med Hypotheses. 2020;140:109637.
David Boothe W, Tarbox JA, Tarbox MB. Atopic dermatitis: pathophysiology. Adv Exp Med Biol. 2017;1027:21-37.
Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018;78:S28-S36.
Maloney NJ, Tegtmeyer K, Zhao J, Worswick S. Dupilumab in dermatology: potential for uses beyond atopic dermatitis. J Drugs Dermatol. 2019;18:S1545961619P1053X.
Chiricozzi A, Maurelli M, Gori N, et al. Dupilumab improves clinical manifestations, symptoms and quality of life in adult patients with chronic nodular prurigo. J Am Acad Dermatol. 2020;83(1):39-45. https://doi.org/10.1016/j.jaad.2020.03.049.
Oosterhaven JAF, Voorberg AN, Romeijn GLE, de Bruin-Weller MS, Schuttelaar MLA. Effect of dupilumab on hand eczema in patients with atopic dermatitis: an observational study. J Dermatol. 2019;46:680-685.
Russo R, Cozzani E, Gasparini G, Parodi A. Targeting interleukin 4 receptor α: a new approach to the treatment of cutaneous autoimmune bullous diseases? Dermatol Ther. 2020;33:e13190.
Khosravi H, Zhang S, Anderson AM, Ferris LK, Choudhary S, Patton T. Dupilumab drug survival, treatment failures, and insurance approval at a tertiary care center in the United States. J Am Acad Dermatol. 2020;82:1023-1024.
Spekhorst LS, Ariëns LF, van der Schaft J, et al. Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: results from the BioDay registry. Allergy. 2020. https://doi.org/10.1111/all.14324.
Calzavara Pinton P, Cristaudo A, Foti C, et al. Diagnosis and management of moderate to severe adult atopic dermatitis: a Consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC), and the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA). G Ital Dermatol Venereol. 2018;153:133-145.
Law Ping Man S, Bouzillé G, Beneton N, Safa G, Dupuy A, Droitcourt C. Drug survival and postdrug survival of first-line immunosuppressive treatments for atopic dermatitis: comparison between methotrexate and cyclosporine. J Eur Acad Dermatol Venereol. 2018;32:1327-1335.
Worm M, Simpson EL, Thaçi D, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2019;156:131-143.
Jo CE, Georgakopoulos JR, Ladda M, et al. Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate to severe atopic dermatitis in clinical practice: a retrospective cohort study. J Am Acad Dermatol. 2020;82:1530-1532. https://doi.org/10.1177/1203475420928907.
de Wijs LEM, Nguyen NT, Kunkeler ACM, et al. Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series. Br J Dermatol. 2019. https://doi.org/10.1111/bjd.18730.
Zhu GA, Chen JK, Chiou A, Ko J, Honari G. Assessment of the development of new regional dermatoses in patients treated for atopic dermatitis with dupilumab. JAMA Dermatol. 2019;155:850-852.
Nettis E, Bonzano L, Patella V, et al. Dupilumab-associated conjunctivitis in patients with atopic dermatitis: a multicenter real-life experience. J Investig Allergol Clin Immunol. 2020;30:201-204. https://doi.org/10.1111/all.14338.
Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181:459-473.
Beck KM, Seitzman GD, Yang EJ, Sanchez IM, Liao W. Ocular co-morbidities of atopic dermatitis. Part ii: ocular disease secondary to treatments. Am J Clin Dermatol. 2019;20:807-815.
Wang S, Zhu R, Gu C, et al. Distinct clinical feature and serum cytokine pattern of elderly atopic dermatitis in China. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16346.
Esaki H, Brunner PM, Renert-Yuval Y, et al. Early-onset pediatric atopic dermatitis is Th2 but also Th17 polarized in skin. J Allergy Clin Immunol. 2016;138:1639-1651.
Silverberg JI. Adult-onset atopic dermatitis. J Allergy Clin Immunol Pract. 2019;7:28-33.
Faulds D, Goa KL, Benfield P. Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs. 1993;45:953-1040.
Drucker AM, Ellis AG, Bohdanowicz M, et al. Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis. JAMA Dermatol. 2020;156:659. https://doi.org/10.1001/jamadermatol.2020.0796.
Fargnoli MC, Esposito M, Ferrucci S, et al. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat. 2019;28:1-7.
Ferrucci S, Casazza G, Angileri L, et al. Clinical response and quality of life in patients with severe atopic dermatitis treated with dupilumab: a single-center real-life experience. J Clin Med. 2020;9:791.